Table 1 Summary of patient characteristics.
Clinical Characteristic | n = 15 |
Age (years) | |
Median | 63 |
Range | 53–75 |
Sex, n (%) | |
Female | 6 (40) |
Male | 9 (60) |
Ethnicity, n (%) | |
White (British, Irish, other) | 14 (93) |
Black (African, British, Caribbean) | 1 (7) |
Asian (Asian, British) | 0 (0) |
other | 0 (0) |
Smoking status, n (%) | |
Never smoker | 1 (6) |
Ex-smoker | 10 (67) |
Smoker | 4 (27) |
ECOG PS, n (%) | |
0 | 4 (27) |
1 | 11 (73) |
Histopathology, n (%) | |
NSCLC-non-squamous | 12 (80) |
NSCLC-squamous | 3 (20) |
Tumour (T) stage, n (%) | |
X | 1 (7) |
1a | 0 (0) |
1b | 2 (13) |
1c | 1 (7) |
2a | 2 (13) |
2b | 0 (0) |
3 | 1 (7) |
4 | 8 (53) |
Node (N) stage, n (%) | |
X | 1 (7) |
0 | 1 (7) |
1 | 0 (0) |
2 | 7 (46) |
3 | 6 (40) |
Metastatic (M) stage, n (%) | |
M0 or Mx | 1 (7) |
M1a | 5 (33) |
M1b | 6 (40) |
M1c | 3 (20) |
PD-L1 TPS (SP263), n (%) | |
< 1% | 5 (33) |
1–49% | 2 (13) |
≥50% | 8 (53) |
Not available | 0 (0) |
Systemic anti-cancer therapy, n (%) | |
Single agent pembrolizumab | 7 (47) |
Pembrolizumab with chemo. | 8 (53) |
- carboplatin + pemetrexed | 6 (40) |
- carboplatin + paclitaxel | 2 (13) |
[99mTc]NM-01 dose (MBq), baseline | |
Mean | 547 |
Median | 541 |
Range | 329–694 |
[99mTc]NM-01 dose (MBq), 9 weeks | (n = 13) |
Mean | 601 |
Median | 629 |
Range | 368–721 |
[18F]FDG dose (MBq), baseline | |
Mean | 337 |
Median | 331 |
Range | 294–379 |
[18F]FDG dose (MBq), 9 weeks | (n = 13) |
Mean | 328 |
Median | 324 |
Range | 287–374 |
